Titlebook: New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere; W. H. H?rl,P. J. Schollmeyer Confere

PLY

書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere影響因子(影響力)




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere影響因子(影響力)學科排名




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere網(wǎng)絡(luò)公開度




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere網(wǎng)絡(luò)公開度學科排名




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere被引頻次




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere被引頻次學科排名




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere年度引用




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere年度引用學科排名




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere讀者反饋




書目名稱New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmaphere讀者反饋學科排名

粉筆

反感

Neutrophil Activation During HemodialysisDialyzing membranes are often used in clinical circumstances and are an important factor in the consideration of biocompatibility with non-biological medical paraphernalia. Depending on the unique physical characteristics of the various filters employed, there are some significant side effects regard to cellular activation.

Libido

Biocompatibility — A System ApproachThe use of more than 2 billion biomaterial devices per year in therapeutic medicine elucidates the magnitude of one of the biggest problems today’s medicine is dealing with. Clinical application of biomaterials has by far exceeded in both quality and quantity our knowledge about the interaction between the biomaterial and the human organism (1).

旁觀者

ADJ

Trigger-Point

Treatment of Uraemic Anaemia with Recombinant Human Erythropoietinn deficiency due to blood losses in the extracorporeal circuit (2); severe hyperparathyroidism with osteitis fibrosa (3) ; abnormally high concentrations of aluminium (4). However, there is general agreement that the main cause of uraemic anaemia is the insufficient production of erythropoietin from the diseased kidneys (5).

Initiative

gain631

Is Continuous Haemofiltration Superior to Intermittent Dialysis and Haemofiltration Treatment? to roughly 70% in 1985 (Fig. 1). These figures are drawn from 212 references in the literature assigned to the date of publication or the date at which the publication was received, even where treatment had taken place earlier. Two causes are generally cited for this rise.

平淡而無味